NEWS

News

December

Philogen S.p.A. announces participation in the “Antibody Engineering & Therapeutics Meeting”, 11 – 15 December 2016, San Diego, CA

  Philogen S.p.A. announces participation in the “Antibody Engineering & Therapeutics Meeting”, 11 – 15 December 2016, San Diego, CA

November

Philogen S.p.A. and its fully owned subsidiary Philochem AG, announce their participation to the “3rd ShanghaiTech-SIAIS BioForum”, 7-10 November 2016, Shanghai, China

  Philogen S.p.A announces participation in the "3rd ShanghaiTech-SIAIS BioForum", 7-10 Shanghai, China


Philogen S.p.A. announces participation in the "World Immunotherapy Congress 2016", 14 - 16 November 2016, Basel, Switzerland

  Philogen S.p.A. announces participatio in the "World Immunotherapy Congress 2016", 14 - 16 November 2016, Basel, Switzerland

October

Philogen S.p.A announces participation in  “PEGS Europe - Protein & Antibody Engineering Summit" , 31 October – 4 November 2016, Lisbon, Portugal

  Philogen S.p.A announces participation in “PEGS Europe - Protein & Antibody Engineering Summit" , 31 October – 4 November 2016, Lisbon, Portuga


Philogen S.p.A. announced that the European Commission (EC) has granted Orphan Drug Designation to L19TNF for the treatment of soft-tissue sarcoma. 

  Philogen S.p.A. receives Orphan Drug Designation for the treatment of soft-tissue sarcoma

August

Philogen S.p.A. announces participation in “XXIV EFMC INTERNATIONAL SYMPOSIUM ON MEDICINAL CHEMISTRY”, 28 August – 1 September 2016, Manchester, UK

  Philogen S.p.A. announces participation in “XXIV EFMC INTERNATIONAL SYMPOSIUM ON MEDICINAL CHEMISTRY”


Philogen S.p.A. announced that they have entered into a collaboration, option and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover and develop a new class of immunomodulatory therapeutics.

  Philogen announced collaboration with Johnson & Johnson Innovation.

July

​Philogen SpA announced the successful GMP production of  PHC-102 for the imaging of renal cell carcinoma and other carbonic anhydrase expressing tumors

  ​Philogen SpA announced the successful GMP production of PHC-102

February

Philogen announce expanded research and development agreement with AbbVie

  Philogen announces expanded research and development agreement with AbbVie

January

Philogen S.p.A. announced that Pfizer Inc. (NYSE: PFE) has exercised options granted under the agreement established in December 2014 for the potential development and commercialization of multiple antibody drug conjugates (ADCs). Siena, Italy, 21st January 2016.

  Press Release Philogen Pfizer ADC option exercise


Philogen S.p.A announced the launch of a pivotal trial in patients with Stage IIIB/C melanoma, following promising results obtained in a Phase II study with an innovative immunotherapeutic approach. Siena, 21st January 2016.
 

  Press release Melanoma Phase III

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all of the cookies, please refer to the cookie policy. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies.

I Accept Cookie Policy
X